Biochemical Engineering Special Interest Group
biological engineering professionals
25 January 2016

US orphan status for Immunocore eye cancer drug

The US Food and Drug Administration has granted Immunocore’s IMCgp100 orphan drug designation for the treatment of uveal melanoma. The move qualifies the UK biotech for a number of development incentives and will enable a fast-track registration for the drug, which is currently in Phase IIa clinical trials for the treatment of late stage cutaneous and uveal melanoma. Source: Pharmatimes 25/1/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).